Premium Nahrungsergänzungsmittel | artgerecht

Hepatic Steatosis: Causes, Symptoms and Treatment

Hepatic steatosis is a condition in which excess fat accumulates in liver cells. It is commonly caused by poor diet, obesity, or alcohol consumption and can progress to serious liver disease if left untreated.

Regular tips about health Regular tips about health

Things worth knowing about "Hepatic Steatosis"

Hepatic steatosis is a condition in which excess fat accumulates in liver cells. It is commonly caused by poor diet, obesity, or alcohol consumption and can progress to serious liver disease if left untreated.

What is Hepatic Steatosis?

Hepatic steatosis, commonly known as fatty liver disease, is a condition in which excess fat builds up inside liver cells. It is diagnosed when more than 5% of liver cells contain fat droplets. The condition is highly prevalent, affecting an estimated 20–30% of adults in Western countries. It often causes no symptoms in its early stages but can progress to serious liver damage if not addressed.

Types of Hepatic Steatosis

There are two main forms of the disease:

Alcoholic Fatty Liver Disease (AFLD): Caused by excessive alcohol consumption, which disrupts normal fat metabolism in the liver.
Non-Alcoholic Fatty Liver Disease (NAFLD): Occurs independently of alcohol and is strongly associated with obesity, type 2 diabetes, and metabolic syndrome. This is currently the most common liver disease worldwide.

Causes

The condition can arise from a range of contributing factors:

A diet high in saturated fats and refined sugars
Overweight and obesity
Physical inactivity
Type 2 diabetes and insulin resistance
Elevated blood lipid levels (hyperlipidemia)
Regular alcohol consumption
Certain medications (e.g., corticosteroids, tamoxifen)
Genetic predisposition

Symptoms

Hepatic steatosis frequently causes no symptoms in its early stages. When symptoms do occur, they may include:

Fatigue and general exhaustion
A dull ache or pressure in the upper right abdomen
Nausea and a feeling of fullness
Reduced physical performance

In advanced stages, if steatohepatitis (liver inflammation) or liver cirrhosis develops, symptoms may include jaundice, fluid accumulation in the abdomen (ascites), and clotting disorders.

Diagnosis

Diagnosis typically involves a combination of the following assessments:

Blood tests: Elevated liver enzymes (ALT, AST, GGT) may indicate liver cell damage.
Ultrasound (sonography): A fatty liver appears brighter than normal on ultrasound and is the most common initial imaging method used.
FibroScan (elastography): Measures liver stiffness, providing an estimate of the degree of fibrosis or scarring.
Liver biopsy: Considered the gold standard for accurately assessing the extent of fat accumulation, inflammation, and fibrosis.

Treatment

There is currently no widely approved specific drug therapy for hepatic steatosis. Treatment primarily focuses on addressing underlying causes:

Weight loss: A reduction of 7–10% of body weight can significantly decrease fat deposits in the liver.
Dietary changes: A Mediterranean-style diet rich in vegetables, legumes, olive oil, and whole grains is strongly recommended.
Regular physical activity: Both aerobic exercise and strength training improve insulin sensitivity and fat metabolism.
Alcohol abstinence: Complete avoidance of alcohol is essential for alcoholic fatty liver disease.
Management of comorbidities: Controlling blood sugar, blood pressure, and cholesterol levels is critical.
Pharmacological options: For non-alcoholic steatohepatitis (NASH), new agents such as resmetirom are gaining approval; vitamin E and GLP-1 receptor agonists have also shown promising results in clinical studies.

Prognosis

When detected early and managed appropriately, hepatic steatosis is often fully reversible. Without intervention, it may progress to steatohepatitis, liver fibrosis, cirrhosis, and ultimately hepatocellular carcinoma (liver cancer). Regular medical follow-up is therefore essential.

References

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO): EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology, 2016.
Chalasani N et al.: The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018.
World Health Organization (WHO): Obesity and overweight – Key facts. WHO Fact Sheet, 2024. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.